Millions of Medicare Part D enrollees who rely on drugs for cancer and chronic conditions will see lower out-of-pocket costs starting January 1, 2027, after the Centers for Medicare & Medicaid Services finalized negotiated prices on 15 additional prescription drugs. Manufacturers have signed participation agreements for this second cycle of the Medicare Drug Price Negotiation Program, locking in what CMS calls Maximum Fair Prices. The gap between that announcement and the 2027 effective date, though, leaves beneficiaries paying current prices for at least another year while Part D plans begin recalibrating their formularies.
Why the 2027 negotiated prices will reshape Part D plan decisions now
The practical effect of setting Maximum Fair Prices more than a year before they take hold is that Part D plan sponsors must start adjusting their formularies and benefit designs well in advance. Plan filings for the 2027 coverage year will be submitted to CMS during 2026, and those filings will reflect whether insurers shift preferred-tier placement toward the 15 negotiated drugs or restructure cost-sharing around the new price ceilings. That sequence means the downstream effects on beneficiary copays and plan premiums will become visible in regulatory filings months before anyone fills a prescription at the lower price.
A reasonable expectation is that Part D plans will move faster than CMS enrollment projections anticipate in steering patients toward these drugs, because plans have a direct financial incentive to lock in the government-negotiated rates. If formulary shifts accelerate, beneficiaries could see indirect benefits, such as improved tier placement, even before the Maximum Fair Prices formally apply. The 2026 plan filing window will be the first concrete test of that dynamic.
CMS second-cycle agreements and the drugs they cover
CMS confirmed that all manufacturers signed agreements to participate in the second negotiation cycle, describing the affected medications as major treatments for cancer and chronic disease among Medicare beneficiaries. The agency framed the negotiated prices as a way to deliver savings for seniors enrolled in Part D while maintaining access to widely used therapies. According to CMS, the Maximum Fair Prices will take effect on January 1, 2027, and will apply across participating Part D plans.
To support beneficiaries, clinicians, and plans, CMS has posted detailed materials on its Medicare Drug Price Negotiation Program, including lists of selected drugs and their timelines. The agency’s program page distinguishes between drugs that already have negotiated prices and those that are still in the negotiation phase. For the second cycle, the 2027 Maximum Fair Prices are now set, giving plans a concrete benchmark for benefit design and contract negotiations with pharmacy benefit managers.
The program is also expanding beyond Part D. In a separate announcement, CMS outlined a third cycle that includes 15 additional drugs selected for negotiation, among them the first Part B products subject to this process. These Part B drugs, typically administered in physician offices or hospital outpatient departments, mark a new front in the agency’s effort to address high-cost therapies. CMS emphasized in its third-cycle release that selection for negotiation does not immediately set prices; it starts a structured process that will culminate in future years.
Two distinct announcements are easy to conflate. The second-cycle drugs already have negotiated prices scheduled to take effect in 2027. The third-cycle drugs have merely been selected for negotiation and will not have final prices until that process concludes. Readers tracking specific medications should consult the CMS program page to confirm which negotiation cycle, and which implementation year, applies to their prescriptions.
Unresolved gaps between announced savings and actual relief
CMS has not publicly released the exact Maximum Fair Price for each of the 15 second-cycle drugs in a simple, consumer-facing press summary, which limits how precisely beneficiaries can estimate future out-of-pocket costs. While the agency projects substantial aggregate savings for Medicare and for seniors, the translation of those savings into individual relief will depend on how plans structure deductibles, coinsurance rates, and tier placement around the new ceilings.
Another open question is how quickly competitive dynamics will pass negotiated savings through to enrollees rather than being absorbed in plan margins or used primarily to restrain premium growth. Plans could, for example, keep premiums relatively flat while modestly lowering coinsurance on the negotiated drugs, or they could prioritize overall premium stability and leave some patient cost-sharing largely unchanged. Because Part D benefit designs are highly variable, the same negotiated price may yield very different experiences for beneficiaries enrolled in different plans or regions.
There is also a timing mismatch between expectations and reality. Public messaging around the negotiation program emphasizes lower drug costs for seniors, but the second-cycle prices will not be in effect until 2027, and the third-cycle drugs will come later still. For patients currently facing high out-of-pocket expenses for these therapies, the near-term impact may feel limited, even as CMS points to long-run structural changes in how Medicare pays for prescription drugs.
For now, beneficiaries and advocates will be watching three milestones. First, CMS guidance to plans over the next year will shape how aggressively sponsors are expected to use the negotiated drugs within their formularies. Second, the 2026 plan filing and 2027 marketing materials will reveal how plans convert Maximum Fair Prices into concrete premiums and copays. Third, once 2027 begins and claims data accumulate, policymakers will be able to assess whether the negotiation program is narrowing the gap between headline savings projections and the day-to-day affordability challenges facing people who depend on these medications.
